Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy

BACKGROUND: The newly synthesized Aurora-A kinase inhibitor XY-4 is a potential anti-cancer agent, but its hydrophobicity and limited efficiency restrict further application. Nanotechnology based combined therapy provides an optimized strategy for solving these issues. METHODS: In this study, the ne...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Nanomedicine
Egile Nagusiak: Duan, Xingmei, Mu, Minjie, Yan, Junfeng, Bai, Lan, Zhong, Lei, Zhu, Yuxuan, Pan, Haixia, Zhang, Mei, Shi, Jianyou
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2018
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5849942/
https://ncbi.nlm.nih.gov/pubmed/29563798
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJN.S147759
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak